Grants for Small businesses - Federal

This funding opportunity supports small businesses in the U.S. to develop innovative technologies that improve health outcomes and reduce disparities for minority populations.

This funding opportunity supports small businesses in the U.S. to develop innovative health solutions that improve outcomes and reduce disparities for minority populations and underserved communities.

This funding opportunity supports U.S.-based small businesses in developing innovative clinical diagnostic tools that address health disparities and improve healthcare access for diverse populations.

This funding opportunity supports U.S.-based small businesses in developing innovative diagnostic tools to reduce health disparities among diverse patient populations.

This program provides financial assistance to farmers and small rural businesses for implementing renewable energy projects and improving energy efficiency.

This funding opportunity provides financial support for small businesses to conduct innovative clinical trials related to allergy and infectious diseases, focusing on high-risk studies and unlicensed products.

The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions

The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions

This funding opportunity provides financial support to small U.S.-based businesses for the development and validation of analytical methods to measure biomarkers related to neurological and neuromuscular disorders, with an emphasis on enhancing inclusivity and collaboration in research.

This Notice of Funding Opportunity (NOFO) invites applications from eligible small businesses to develop solutions for commercialization that can be used to enable regional clinician-to-clinician genomic medicine eConsult services. Specifically, we seek products, such as technologies or services, that will allow for the development and sustainment of eConsult services. Eligible United States small business concerns (SBCs) may submit Small Business Technology Transfer (STTR) Phase I, and Fast-Track grant applications. Small business applicants interested in submitting a Small Business Innovation Research (SBIR) grant application should submit to the related funding opportunity, PAR-24-106. SBIR and STTR are phased programs. The main objective in SBIR and STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts. An SBIR and STTR Phase II continues the R&D efforts to advance the technology toward ultimate commercialization. At the conclusion of an SBIR/STTR Phase II, it is expected that the small business will fully commercialize their product or technology using non-SBIR/STTR funds (either federal or non-federal). Small businesses that are eligible to submit Phase II applications for projects that were supported with a Phase I SBIR or STTR award are expected to submit the regular Phase II application as a "Renewal" application based on the awarded Phase I SBIR or STTR project. Only one Phase II application may be awarded for a specific project supported by a Phase I award.

This Notice of Funding Opportunity (NOFO) invites applications from eligible small businesses to develop solutions for commercialization that can be used to enable regional clinician-to-clinician genomic medicine eConsult services. Specifically, we seek products, such as technologies or services, that will allow for the development and sustainment of eConsult services. Eligible United States small business concerns (SBCs) may submit Small Business Innovation Research (SBIR) Phase I, Direct to Phase II, and Fast-Track grant applications. Small business applicants interested in submitting a Small Business Technology Transfer (STTR) grant application should submit to the related funding opportunity, PAR-24-107. SBIR and STTR are phased programs. The main objective in SBIR and STTR Phase I is to establish the technical merit and feasibility of the proposed research and development efforts. An SBIR and STTR Phase II continues the R&D efforts to advance the technology toward ultimate commercialization. At the conclusion of an SBIR/STTR Phase II, it is expected that the small business will fully commercialize their product or technology using non-SBIR/STTR funds (either federal or non-federal). Small businesses that are eligible to submit Phase II applications for projects that were supported with a Phase I SBIR or STTR award are expected to submit the regular Phase II application as a "Renewal" application based on the awarded Phase I SBIR or STTR project. Only one Phase II application may be awarded for a specific project supported by a Phase I award. NIH Fast-Track: An NIH SBIR Fast-Track incorporates a submission and review process in which both Phase I and Phase II applications are submitted and reviewed together as one application to reduce or eliminate the funding gap between phases. NIH Direct to Phase II: For small businesses that have already demonstrated scientific and technical merit and feasibility but have not received a Phase I SBIR or STTR for that project, NIH can issue a Direct to Phase II award. The NIH will accept Direct to Phase II applications regardless of the funding source for the proof of principle work on which the proposed Phase II research is based. Direct to Phase II awards should be submitted as “New” applications and not continuations ("Renewal") of Phase I SBIR or STTR projects.

This Notice of Funding Opportunity (NOFO) invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout and other genetically-engineered mutant mice and related biomaterials. MMRRC strains are held to the highest standards to optimize reproducibility of studies and assure scientific rigor and transparency; all submitted strains are thoroughly reviewed and documented and include additional quality control measures. The Program Director/Principal Investigator (PD/PI) of each MMRRC in addition to the major resource activities is required to develop a small high risk, high return, research pilot project that complements the goals and needs of the MMRRC consortium. ORIP intends to fund up to four awards, but the overall number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications Award Budget Requested Direct Costs must reflect actual needs of the project. For Renewal (a.k.a. Type 2) applications, no more than a 5 percent (direct cost) increase from the last non-competing year will be accepted. ORIP intends to fund up to four awards, but the overall number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications

The Lithium-Ion Battery Recycling Prize is a grant opportunity for creative individuals, entrepreneurs, and businesses to address challenges in the lithium-ion battery recycling supply chain. The goal of this phased prize competition is to develop and demonstrate processes that can capture 90% of all discarded or spent lithium-ion batteries in the United States for recovery of key materials. The continuation of the prize will award a total of $7.4 million in cash prizes and voucher support over the next 3 years. This includes a new competition track for new competitors and previous participants, as well as additional support for Phase III winning teams. Breakthrough, a new public contest, aims to incentivize innovative solutions from battery industry entrepreneurs that align with the prize goal. Up to $2.4 million in cash prizes and voucher funding will be awarded to up to 10 winners. Winners will also have the opportunity to advance to Phase IV of the competition. Qualified lithium-ion battery recyclers and second-life testing organizations are also being sought as Evaluation Entities for Phase IV. More information about becoming an Evaluation Entity can be found on the American-Made website.

This funding opportunity supports existing Centers for AIDS Research in expanding training and research initiatives focused on HIV and health disparities, particularly for underrepresented groups and early-career investigators.

This funding opportunity supports small businesses in conducting early-stage clinical trials for innovative treatments of vision-related disorders, ensuring safety and collaboration with the National Eye Institute.

This funding opportunity provides financial support to small businesses in the U.S. for conducting early-phase clinical trials of innovative treatments for neurological disorders.

This funding opportunity provides financial support for small businesses to conduct exploratory clinical trials focused on neurological disorders, including the development of drugs, devices, and therapies.

This funding opportunity supports U.S.-based small businesses in developing automated and miniaturized systems that replicate human tissue functions for improved drug testing and biomedical research.

This funding opportunity supports U.S. small businesses in developing automated and miniaturized tissue chip systems to improve biomedical research and drug development.

This funding opportunity provides financial support to institutions with active Clinical and Translational Science Awards to develop innovative programs that address critical challenges in clinical research and improve the efficiency of translating scientific discoveries into practical applications.